tetano
Editor, Senior Moderator
Crit Care Explor
. 2022 Aug 29;4(9):e0754.
doi: 10.1097/CCE.0000000000000754. eCollection 2022 Sep.
Presence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus-2 on Admission Is Associated With Decreased Mortality in COVID-19 Critical Illness
F Linzee Mabrey[SUP] 1 [/SUP], Leila R Zelnick[SUP] 2 [/SUP], Eric D Morrell[SUP] 1 3 [/SUP], Nicholas G O'Connor[SUP] 1 [/SUP], Andrew Hart[SUP] 1 [/SUP], Mark M Wurfel[SUP] 1 3 [/SUP], W Conrad Liles[SUP] 3 4 [/SUP], Pavan K Bhatraju[SUP] 1 3 [/SUP]
Affiliations
Abstract
To determine whether the early serologic response in COVID-19 critical illness is associated with hospital mortality. To evaluate if time-to-seroconversion differs by receipt of dexamethasone therapy.
Design: Patients were prospectively enrolled within 24 hours of ICU admission from two University of Washington Hospitals. Plasma was collected on enrollment and on days 3, 7, 10, and 14.
Setting: ICUs between March 2020 and April 2021.
Patients: Consecutive adults with COVID-19 admitted to an ICU.
Measurements and main results: We measured longitudinal total antispike protein antibody levels (anti-S abs) and total antinucleocapsid antibody levels (anti-N ab) using a U.S. Food and Drug Administration-authorized Roche instrument. We evaluated whether detectable anti-S abs on ICU admission were associated with host factors, initial disease severity, and hospital mortality. We evaluated whether dexamethasone therapy was associated with time-to-seroconversion. Among 93 unvaccinated participants, 47 (51%) had detectable anti-S abs on ICU admission. There was no difference in Acute Physiology and Chronic Health Evaluation II score or time between first positive severe acute respiratory syndrome coronavirus-2 PCR and ICU admission in those with detectable versus undetectable anti-S abs. Adjusting for age, body mass index, and sex, patients with detectable anti-S abs had a lower risk of inhospital death (hazard ratio, 0.40; 95% CI, 0.17-0.94; p = 0.04). Among 21 patients with undetectable anti-S abs on ICU admission and serial measurements available, time-to-seroconversion was not significantly affected by receipt of dexamethasone therapy.
Conclusions: In COVID-19 critical illness, a significant proportion of patients do not have detectable antibodies at ICU admission, and this is independent of severity of illness. Detectable anti-S abs were associated with lower risk of inhospital death. Despite concern that corticosteroids may impair an appropriate antiviral serologic response, early antibody kinetics were not significantly affected by administration of dexamethasone; however, CIs were wide and require further study.
Keywords: COVID 19 critical illness; adaptive immunity; severe acute respiratory syndrome coronavirus 2 antibody response; viral antibody response.
. 2022 Aug 29;4(9):e0754.
doi: 10.1097/CCE.0000000000000754. eCollection 2022 Sep.
Presence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus-2 on Admission Is Associated With Decreased Mortality in COVID-19 Critical Illness
F Linzee Mabrey[SUP] 1 [/SUP], Leila R Zelnick[SUP] 2 [/SUP], Eric D Morrell[SUP] 1 3 [/SUP], Nicholas G O'Connor[SUP] 1 [/SUP], Andrew Hart[SUP] 1 [/SUP], Mark M Wurfel[SUP] 1 3 [/SUP], W Conrad Liles[SUP] 3 4 [/SUP], Pavan K Bhatraju[SUP] 1 3 [/SUP]
Affiliations
- PMID: 36050993
- PMCID: PMC9426803
- DOI: 10.1097/CCE.0000000000000754
Abstract
To determine whether the early serologic response in COVID-19 critical illness is associated with hospital mortality. To evaluate if time-to-seroconversion differs by receipt of dexamethasone therapy.
Design: Patients were prospectively enrolled within 24 hours of ICU admission from two University of Washington Hospitals. Plasma was collected on enrollment and on days 3, 7, 10, and 14.
Setting: ICUs between March 2020 and April 2021.
Patients: Consecutive adults with COVID-19 admitted to an ICU.
Measurements and main results: We measured longitudinal total antispike protein antibody levels (anti-S abs) and total antinucleocapsid antibody levels (anti-N ab) using a U.S. Food and Drug Administration-authorized Roche instrument. We evaluated whether detectable anti-S abs on ICU admission were associated with host factors, initial disease severity, and hospital mortality. We evaluated whether dexamethasone therapy was associated with time-to-seroconversion. Among 93 unvaccinated participants, 47 (51%) had detectable anti-S abs on ICU admission. There was no difference in Acute Physiology and Chronic Health Evaluation II score or time between first positive severe acute respiratory syndrome coronavirus-2 PCR and ICU admission in those with detectable versus undetectable anti-S abs. Adjusting for age, body mass index, and sex, patients with detectable anti-S abs had a lower risk of inhospital death (hazard ratio, 0.40; 95% CI, 0.17-0.94; p = 0.04). Among 21 patients with undetectable anti-S abs on ICU admission and serial measurements available, time-to-seroconversion was not significantly affected by receipt of dexamethasone therapy.
Conclusions: In COVID-19 critical illness, a significant proportion of patients do not have detectable antibodies at ICU admission, and this is independent of severity of illness. Detectable anti-S abs were associated with lower risk of inhospital death. Despite concern that corticosteroids may impair an appropriate antiviral serologic response, early antibody kinetics were not significantly affected by administration of dexamethasone; however, CIs were wide and require further study.
Keywords: COVID 19 critical illness; adaptive immunity; severe acute respiratory syndrome coronavirus 2 antibody response; viral antibody response.